Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: teriparatide
DATE: 20/10/2020
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
PRIVACY POLICY
SUBSCRIBE
